Celularity Inc. · NASDAQ:CELU
Celularity — Investor Presentation (May 2023)
14 slides from Celularity's investor presentation, May 31, 2023
Slide 1: The Next Evolution in Cellular Medicine
THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023
Slide 2: Forward-looking statements
All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “forward-looking statements” reflecting management’s current beliefs and expectations, including those relating to future events. In some cases, you can identify forward-looking
Slide 3: About Celularity
ABOUT CELULARITY Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial-based therapeutics products. Our IMPACT platform capitalizes on the benefits of placental-derived stem, prog
Slide 4: Celularity's Vision
CELULARITY’S VISION Lead the transformative potential of placental-derived therapeutics: advance the discovery of the placenta as an abundant, renewable source of advanced biomaterials and newborn cells, which are biologically preferred to cells from adult bone marrow or peripheral blood. Target hig
Slide 5: Celularity: Company History
CELULARITY: COMPANY HISTORY Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation KEY: CORPORATE MILESTONE CLINICAL MILESTONE FINANCIAL MILESTONE 2000 – Anthrogenesis Corporation – Founded by Dr. Robert Hariri 2002 – Anthrogenesis acquired by Celgene, becomes Celgene Cellu
Slide 6: Our Experienced Leadership Team
OUR EXPERIENCED LEADERSHIP TEAM With Deep Expertise in Cell Therapy and Advanced Biomaterials John Haines Senior EVP, GM & Chief Administrative Officer David Beers, CFA Chief Financial Officer Robert J. Hariri, M.D., Ph.D. Chairperson, Founder, & CEO Anthrogenesis C O R P O R A T I O N Stephen Brigi
Slide 7: Celularity Placental-Derived Product Platform
CELULARITY PLACENTAL-DERIVED PRODUCT PLATFORM Leveraging the Benefits of Placental-Derived Cells and Biomaterials to Target Multiple Diseases Postpartum Placenta Abundant, reliable, renewable and biologically consistent raw material Nature’s ‘professional’ universal donor tissue +140 Million Worldwi
Slide 8: Single-Source, Placental-Based Platform Driving Broad Pipeline
SINGLE SOURCE MATERIAL Placenta T-Cell Genetically Modified NK Unmodified NK Mesenchymal-like Adherent Stromal Cells 7 KEY PROGRAMS CYNK-301 CYNK-001 APPL-001 > 7 INITIAL INDICATIONS Crohn’s CYCART-19 NHL, MCL AML AML ALLOGENEIC CELL TYPES AND ADVANCED BIOMATERIALS Other indications CYNK-302 NSCLC C
Slide 9: Manufacturing Overview
Celularity benefits from Celgene’s 15 year+ investment in developing the technologies and capabilities required to manufacture cellular products at scale with consistent and reliable quality MANUFACTURING OVERVIEW Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translat
Slide 10: Cell Therapy Clinical Pipeline
PRE-CLINICAL CLINICAL Hematological Malignancies Platform Functionality Indication Discovery IND-Enabling Phase 1/2 Phase 2/3 CYNK-001 pNK Unmodified AML CYNK-301 pNK IL15 + Marrow Homing + CAR AML CYCART-19 pT CD19 + TCR KO NHL, MCL CYCART-201 pT CD16 + TCR KO + mAb NHL, MCL Solid Tumor Platform Fu
Slide 11: Advanced Biomaterial Products Pipeline
Degenerative Diseases Indication Discovery Regulatory Phase 1/2 Brands Placental Connective Tissue Matrix Integumental Tissue Replacement Amniotic Membrane Allograft Wound Covering Tri-Layer Amniotic Membrane Allograft Wound Covering Tri-Layer Amniotic Membrane Allograft Protective Cover Connective
Slide 12: Current Commercial Portfolio
CURRENT COMMERCIAL PORTFOLIO Degenerative Diseases Improving Patients Health with Placental-Derived Advanced Biomaterial Products Page 12
Slide 13: Degenerative Disease Portfolio
DEGENERATIVE DISEASE PORTFOLIO Commercial Opportunities Deliver Revenue Biovance®: Intact, natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Biovance 3L: a trilayer human amniotic membrane product f
Slide 14: The Next Evolution in Cellular Medicine
THE NEXT EVOLUTION IN CELLULAR MEDICINE